Rating Change
Stifel reiterated its Buy rating on Pulmonx Corporation (NASDAQ:LUNG) on October 28, 2026.
Stifel reiterated its Buy rating on Pulmonx Corporation (NASDAQ:LUNG) on October 28, 2026.

At publication ·
Pulmonx Corporation (NASDAQ:LUNG) · reiterate
At a glance
Stifel reiterated its Buy rating on Pulmonx Corporation (NASDAQ:LUNG) on October 28, 2026.
Pulmonx Corporation operates in the Healthcare sector. The stock currently trades at $2.52 with a market capitalization of $103.7M.
Analyst coverage from Stifel provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Pulmonx Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 28, 2026 | Stifel | Buy | N/A |
| Apr 30, 2026 | D. Boral Capital | Buy | N/A |
| Mar 05, 2026 | D. Boral Capital | Buy | N/A |
| Mar 05, 2026 | Canaccord Genuity | Buy | N/A |
| Feb 20, 2026 | D. Boral Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LUNG Stock Page
A rating of Buy from Stifel reflects the analyst's outlook on Pulmonx Corporation (NASDAQ:LUNG). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LUNG forecast page.
Keep reading
Current market data
NASDAQ · LUNG
$3.01
Down: -$0.16 · -5.06%
Live quote updated